公开(公告)号：US20040063720A1

公开(公告)日：2004-04-01

申请号：US10677687

申请日：2003-10-02

Applicant: Merck & Co., Inc.

Inventor： Mark T. Bilodeau ,  George D. Hartman ,  Jacob M. Hoffman JR. ,  John T. Sisko ,  Peter J. Manley ,  Anthony M. Smith ,  Thomas J. Tucker ,  William C. Lumma JR. ,  Leonard Rodman

IPC: A61K031/497

CPC classification number: C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D487/08 ,  C07D491/08

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

公开(公告)号：US20040038944A1

公开(公告)日：2004-02-26

申请号：US10646593

申请日：2003-08-22

Applicant: Merck & Co., Inc.

Inventor： Donald R. Thompson

IPC: A61K031/675

CPC classification number: A61K31/66 ,  A61K31/663

Abstract: The present invention relates to compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses. The present invention further relates to compositions and methods for alleviating pain associated with skeletal injuries in horses and to treating skeletal injuries in horses.

Abstract translation: 本发明涉及预防或减少马匹骨骼损伤风险或发生率的组合物和方法。 本发明还涉及用于减轻与马骨骼损伤相关的疼痛和治疗马匹骨骼损伤的组合物和方法。

公开(公告)号：US20030228329A1

公开(公告)日：2003-12-11

申请号：US10461030

申请日：2003-06-13

Applicant: Merck & Co., Inc.

Inventor： Ling Chen ,  John W. Shiver ,  Andrew J. Bett ,  Danilo R. Casimiro ,  Michael J. Caulfield ,  Michael A. Chastain ,  Emilio A. Emini

IPC: A61K039/12 ,  C12N007/00 ,  C12N015/867 ,  C12N015/861

CPC classification number: C12N15/86 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C12N2710/10343 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12Q1/703

Abstract: An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.

公开(公告)号：US20030166144A1

公开(公告)日：2003-09-04

申请号：US10303204

申请日：2002-11-25

Applicant: Merck & Co., Inc.

Inventor： Joseph P. Arena ,  Doris F. Cully ,  Scott D. Feighner ,  Andrew D. Howard ,  Paul A. Liberator ,  James M. Schaeffer ,  Leonardus H. T. Van Der Ploeg

IPC: C12P021/02 ,  C07K014/72 ,  C07H021/04 ,  C12N005/06

CPC classification number: C07B59/002 ,  A61K38/00 ,  C07K14/723

Abstract: Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors may be used to screen and identify compounds which bind to the growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and recovering from hip fracture and osteoporosis.

公开(公告)号：US20030153760A1

公开(公告)日：2003-08-14

申请号：US10324956

申请日：2002-12-20

Applicant: Merck & Co., Inc.

Inventor： Paul Devine ,  Hansen Karl

IPC: C07F017/02 ,  C07D487/04 ,  C07C033/46

CPC classification number: C07F17/02 ,  C07B2200/07 ,  C07C17/12 ,  C07C29/143 ,  C07C29/88 ,  C07C33/46 ,  C07C45/004 ,  C07F15/0046 ,  C07F15/0073 ,  C07C25/13 ,  C07C49/80

Abstract: The present invention is concerned with novel processes for the preparation of (R)-1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-ol. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.

Abstract translation: 本发明涉及制备（R）-1-（3,5-双（三氟甲基）苯基）乙-1-醇的新方法。 该化合物可用作合成具有药理活性的化合物的中间体。

公开(公告)号：US20030153600A1

公开(公告)日：2003-08-14

申请号：US10342380

申请日：2003-01-14

Applicant: Merck & Co., Inc.

Inventor： Louis S. Crocker ,  Ian W. Davies ,  Richard G. Osifchin ,  Andrew Kotliar

IPC: A61K031/444 ,  C07D41/04

CPC classification number: C07D213/61

Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: 1 which is useful in the treatment of cyclooxygenase-2 mediated diseases. The invention encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising the Form V polymorph of Compound A. The invention also encompasses a process for synthesizing the Form V polymorph of Compound A.

公开(公告)号：US20030144327A1

公开(公告)日：2003-07-31

申请号：US10342379

申请日：2003-01-14

Applicant: Merck & Co., Inc.

Inventor： Louis S. Crocker

IPC: A61K031/444 ,  C07D41/04

CPC classification number: A61K31/444 ,  C07D213/61

Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: 1 are disclosed. The compound is a potent and selective cyclooxygenase -2 (COX-2) inhibitor.

Abstract translation: 公开了具有以下结构的标题化合物的多晶型，无定形和水合形式。 该化合物是一种有效和选择性的环加氧酶-2（COX-2）抑制剂。

公开(公告)号：US20030055239A1

公开(公告)日：2003-03-20

申请号：US10100405

申请日：2002-03-18

Applicant: Merck & Co., Inc.

Inventor： Richard L. Kendall ,  Kenneth A. Thomas ,  Xianzhi Mao ,  Andrew Tebben

IPC: C07K014/705 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

CPC classification number: C07K14/71 ,  C07K2319/00 ,  G01N2333/71

Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.

公开(公告)号：US20020177617A1

公开(公告)日：2002-11-28

申请号：US10106845

申请日：2002-03-26

Applicant: Merck & Co., Inc.

Inventor： Kremena Simitchieva ,  Scott A. Reines ,  Errol McKinney ,  Eric J. Sandquist ,  Deepak K. Khannna ,  Richard Hargreaves

IPC: A61K031/421 ,  A61K031/415

CPC classification number: A61K31/42 ,  A61K31/40 ,  A61K31/415 ,  A61K31/54 ,  A61K45/06 ,  A61K31/41 ,  A61K2300/00

Abstract: A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.

公开(公告)号：US20020160441A1

公开(公告)日：2002-10-31

申请号：US10128869

申请日：2002-04-24

Applicant: Merck & Co., Inc.

Inventor： Jennifer Nielsen-Kahn ,  Michael C. Justice ,  Dennis M. Schmatz ,  Ming-Jo Hsu ,  Theresa W. Ku

IPC: C12Q001/18 ,  C12N001/18 ,  C12N001/10

CPC classification number: C07K14/00 ,  C12Q1/025 ,  C12Q1/18

Abstract: Inhibition of protein elongation factor 2 provides a target for identifying potential antifungal and antiparasitic compounds. EF2 inhibitors are useful as therapeutic agents against fungal and parasitic infections.

Abstract translation: 蛋白质延伸因子2的抑制提供了鉴定潜在抗真菌和抗寄生虫化合物的靶标。 EF2抑制剂可用作抗真菌和寄生虫感染的治疗剂。